{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:32Z","timestamp":1790395472989,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1681\/asn.2015030337","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T21:40:07Z","timestamp":1437082807000},"page":"952-962","source":"Crossref","is-referenced-by-count":49,"title":["Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch\u20132-Year Follow-Up"],"prefix":"10.1681","volume":"27","author":[{"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Canaan-K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Reiermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Stypmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurcan","family":"\u00dc\u00e7eyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Werner","family":"Hense","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan-Martin","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-32-20230208","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease.","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"R2-32-20230208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry\u2019s disease.","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-32-20230208","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial.","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R4-32-20230208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial.","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R5-32-20230208","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"R6-32-20230208","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: An analysis of registry data.","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"R7-32-20230208","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease.","volume":"152","author":"Wraith","year":"2008","journal-title":"J Pediatr"},{"key":"R8-32-20230208","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1681\/ASN.2013121322","article-title":"Fabry disease: Dose matters.","volume":"25","author":"Warnock","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R9-32-20230208","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.11.155","article-title":"Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).","volume":"102","author":"Linthorst","year":"2011","journal-title":"Mol Genet Metab"},{"key":"R10-32-20230208","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gim.2012.39","article-title":"Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).","volume":"14","author":"Tsuboi","year":"2012","journal-title":"Genet Med"},{"key":"R11-32-20230208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/8904_2012_177","article-title":"Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.","volume":"9","author":"Pisani","year":"2013","journal-title":"JIMD Rep"},{"key":"R12-32-20230208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R13-32-20230208","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","article-title":"Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.","volume":"25","author":"Weidemann","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"R14-32-20230208","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R15-32-20230208","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-32-20230208","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study.","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"R18-32-20230208","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: Evidence for a better outcome with early treatment.","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"R19-32-20230208","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0000000000001333","article-title":"Thromboembolic events in Fabry disease and the impact of factor V Leiden.","volume":"84","author":"Lenders","year":"2015","journal-title":"Neurology"},{"key":"R20-32-20230208","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"R21-32-20230208","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease.","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R22-32-20230208","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"R23-32-20230208","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.ki.5000073","article-title":"Glomerular filtration rate estimated by cystatin C among different clinical presentations.","volume":"69","author":"Rule","year":"2006","journal-title":"Kidney Int"},{"key":"R24-32-20230208","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2011.09.001","article-title":"The role of cystatin C in improving GFR estimation in the general population.","volume":"59","author":"Eriksen","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R25-32-20230208","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2215\/CJN.01240213","article-title":"GFR estimating equations: Getting closer to the truth?","volume":"8","author":"Rule","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-32-20230208","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function.","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med"},{"key":"R27-32-20230208","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease.","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"R28-32-20230208","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1681\/ASN.2004100854","article-title":"Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study.","volume":"16","author":"Perkins","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R29-32-20230208","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2337\/diacare.18.4.572","article-title":"Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.","volume":"18","author":"Mogensen","year":"1995","journal-title":"Diabetes Care"},{"key":"R30-32-20230208","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria.","volume":"20","author":"Witte","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R32-32-20230208","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/gim.2014.79","article-title":"Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: Does the dose really matter?","volume":"17","author":"Pisani","year":"2015","journal-title":"Genet Med"},{"key":"R33-32-20230208","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201603000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:26:46Z","timestamp":1786130806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201603000-00032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2015030337","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}